Additionally, CD19/20- and BCMA-targeting BsAb have been associated with hypogammaglobulinemia, as an on-target, off-tumor effect [46], with depletion in IgG1 and IgG3 subclasses associated with an increased risk of CMV [50,51]. Here, CD19 is linked to neoplasm.